https://www.taxtmi.com/news?id=69410 The Budget proposes Biopharma SHAKTI with Rs 10,000 crore over five years to build domestic biologics and biosimilars manufacturing capacity, expand NIPER education infrastructure, create 1,000 accredited clinical trial sites, and strengthen the Central Drugs Standard Control Organisation with a scientific review cadre to meet global approval timeframes; it also exempts basic customs duty on 17 drugs and extends import duty exemptions for personal imports related to seven additional rare diseases. en-us Sun, 01 Feb 2026 13:46:03 +0530 Sun, 01 Feb 2026 13:46:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=69410 The Budget proposes Biopharma SHAKTI with Rs 10,000 crore over five years to build domestic biologics and biosimilars manufacturing capacity, expand NIPER education infrastructure, create 1,000 accredited clinical trial sites, and strengthen the Central Drugs Standard Control Organisation with a scientific review cadre to meet global approval timeframes; it also exempts basic customs duty on 17 drugs and extends import duty exemptions for personal imports related to seven additional rare diseases. News - Sun, 01 Feb 2026 13:46:03 +0530 https://www.taxtmi.com/news?id=69410